Preclinical safety profile of RC88-ADC：a novel mesothelin-targeted antibody conjugated with Monomethyl auristatin E-Reference-Cited by-同舟云学术

Preclinical safety profile of RC88-ADC：a novel mesothelin-targeted antibody conjugated with Monomethyl auristatin E

Published:2021-11-28 Issue: Volume: Page:1-11
ISSN:0148-0545
Container-title:Drug and Chemical Toxicology
language:en
Short-container-title:Drug and Chemical Toxicology

Author:

Jiang Jing¹,Li Shenjun²^ORCID,Tang Naping³,Wang Ling²,Xin Wei²,Li Shoufeng⁴

Affiliation:

1. Binzhou Medical University, Yantai, China

2. RemeGen Co. Ltd, Yantai, China

3. National Shanghai Center for New Drug Safety Evaluation and Research, Shanghai, China

4. YanTai University, Yantai, China

Funder

National Science and Technology Major Project of China

Publisher

Informa UK Limited

Subject

Chemical Health and Safety,Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health,Pharmacology,Toxicology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/01480545.2021.2005085

Reference15 articles.

1. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer

2. Antibody-Drug Conjugates for Cancer Therapy

3. Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications

4. Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies

5. Preclinical safety profile of disitamab vedotin：a novel anti-HER2 antibody conjugated with MMAE

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research progress of antibody–drug conjugates in gynecologic cancer;Holistic Integrative Oncology;2024-08-29

2. Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy;Pharmaceutical Research;2024-02-17

3. Future potential targets of antibody-drug conjugates in breast cancer;The Breast;2023-06

4. A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer;Frontiers in Pharmacology;2022-12-22